Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Oct 2, 2013
Market Yawns at Government Shutdown
The S&P 500 and Dow are resilient in the wake of a government shutdown. Sep 20, 2013
The Fed Won’t Taper
The Federal Reserve has no plans to taper bond purchases at this time even as the Philly Fed survey suggests expansionary economic activity. Sep 17, 2013
Summers Bows Out
Fed Chairman frontrunner Larry Summers won’t pursue the nomination, and all signs point to Janet Yellen as the replacement for Ben Bernanke. Aug 15, 2013
Eli Lilly Might Have a Blockbuster Cancer Drug
A lung cancer treatment could be a new billion dollar opportunity at Eli Lilly. Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013. Jun 15, 2013
Why Valuentum's Email Transaction Alerts Are Worth Paying Attention To
We take a look at the value generated by our transaction alert emails. The findings are startling! Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment. Jan 22, 2013
Johnson & Johnson’s Long-term Tailwinds Are Intact
Johnson & Johnson reported solid fourth-quarter results. The firm's long-term tailwinds remain intact. Sep 14, 2012
Covidien Will Continue to Drive Solid Shareholder Returns
Covidien provided strong fiscal year 2013 guidance, and the firm continues to return cash to shareholders at a healthy clip. Aug 29, 2012
WellPoint Rallies after Ousting CEO
WellPoint CEO Angela Braley resigned as a result of pressure from shareholders. We still prefer the Health Care SPDR ETF. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
